Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Agreement and Correlation Between Different Topical Corticosteroid Potency Classification Systems

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab: A Case Series

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Subcutaneous Fat Necrosis of the Newborn

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Can patient-reported outcome measures be used to predict consultation needs in patients with psoriasis? A survey study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy

    Publikation: Bidrag til tidsskriftLetterpeer review

  • SPIN MTX Consensus Survey Study Group
Vis graf over relationer

Importance: A clear dosing regimen for methotrexate in psoriasis is lacking, and this might lead to a suboptimal treatment. Because methotrexate is affordable and globally available, a uniform dosing regimen could potentially optimize the treatment of patients with psoriasis worldwide.

Objective: To reach international consensus among psoriasis experts on a uniform dosing regimen for treatment with methotrexate in adult and pediatric patients with psoriasis and identify potential future research topics.

Design, Setting, and Participants: Between September 2020 and March 2021, a survey study with a modified eDelphi procedure that was developed and distributed by the Amsterdam University Medical Center and completed by 180 participants worldwide (55 [30.6%] resided in non-Western countries) was conducted in 3 rounds. The proposals on which no consensus was reached were discussed in a conference meeting (June 2021). Participants voted on 21 proposals with a 9-point scale (1-3 disagree, 4-6 neither agree nor disagree, 7-9 agree) and were recruited through the Skin Inflammation and Psoriasis International Network and European Academy of Dermatology and Venereology in June 2020. Apart from being a dermatologist/dermatology resident, there were no specific criteria for participation in the survey. The participants worked mainly at a university hospital (97 [53.9%]) and were experienced in treating patients with psoriasis with methotrexate (163 [91.6%] had more than 10 years of experience).

Main Outcomes and Measures: In a survey with eDelphi procedure, we tried to reach consensus on 21 proposals. Consensus was defined as less than 15% voting disagree (1-3). For the consensus meeting, consensus was defined as less than 30% voting disagree.

Results: Of 251 participants, 180 (71.7%) completed all 3 survey rounds, and 58 participants (23.1%) joined the conference meeting. Consensus was achieved on 11 proposals in round 1, 3 proposals in round 2, and 2 proposals in round 3. In the consensus meeting, consensus was achieved on 4 proposals. More research is needed, especially for the proposals on folic acid and the dosing of methotrexate for treating subpopulations such as children and vulnerable patients.

Conclusions and Relevance: In this eDelphi consensus study, consensus was reached on 20 of 21 proposals involving methotrexate dosing in patients with psoriasis. This consensus may potentially be used to harmonize the treatment with methotrexate in patients with psoriasis.

OriginalsprogEngelsk
TidsskriftJAMA Dermatology
Vol/bind158
Udgave nummer5
Sider (fra-til)561-572
Antal sider12
ISSN2168-6068
DOI
StatusUdgivet - maj 2022

ID: 76601708